Sancilio L F, Pinkus L M, Jackson C B, Munson H R
Department of Pharmacology, A.H. Robins Research Laboratories, Richmond, VA 23261-6609.
Eur J Pharmacol. 1990 Jun 8;181(3):303-6. doi: 10.1016/0014-2999(90)90094-m.
Zacopride administered orally was more emetic in fed than in fasted ferrets. The emetic activity of zacopride (0.1 mg/kg p.o.) was inhibited (100%) by 0.1 mg/kg i.p. of zacopride and 1 mg/kg i.p. of ICS 205-930. Haloperidol (3.16 mg/kg i.p.) and prochlorperazine (3.16 mg/kg i.p.) were weakly effective. N-acetyl-5-hydroxytryptophyl-5-hydroxytryptophan amide, a 5-HT1P antagonist, was inactive. Thus, the emetic activity of zacopride, like that of cisplatin, is blocked by 5-HT3 receptor antagonists.
口服扎考必利在进食的雪貂中比在禁食的雪貂中催吐作用更强。扎考必利(0.1毫克/千克,口服)的催吐活性被腹腔注射0.1毫克/千克的扎考必利和1毫克/千克的ICS 205 - 930抑制(100%)。氟哌啶醇(3.16毫克/千克,腹腔注射)和丙氯拉嗪(3.16毫克/千克,腹腔注射)效果较弱。5 - HT1P拮抗剂N - 乙酰 - 5 - 羟色胺基 - 5 - 羟色氨酸酰胺无活性。因此,扎考必利的催吐活性与顺铂一样,可被5 - HT3受体拮抗剂阻断。